Z Squared Inc. (ZSQR): Nasdaq/NYSE listing notice — Coeptis receives Nasdaq deficiency notice for minimum bid price non-compliance

Z Squared Inc.

Nasdaq notified Coeptis that its common stock closing bid price was below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until July 29, 2024, to regain compliance by closing at $1.00 for 10 consecutive days.
If not cured, a second 180-day extension may be available if other listing standards are met.
Delisting could reduce liquidity, limit capital access, and trigger penny stock rules, per updated risk factors.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Z Squared Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 29, 2024, Coeptis Therapeutics Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Notice”). The Notice has no immediate effe

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Z Squared Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-000615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.